EFFICACY OF UPADACITINIB AS AN INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS, WITH OR WITHOUT PREVIOUS TREATMENT FAILURE OF BIOLOGIC THERAPY: DATA FROM THE DOSE-RANGING PHASE 2B STUDY U-ACHIEVE

(1) University of Calgary,Calgary,Canada

(2) Academic Medical Center,Amsterdam,Netherlands

(3) University of California,San Diego,United States

(4) Institute Of Translational Medicine,Birmingham,United Kingdom

(5) Universität Kiel UKSH Medizinische Abt. I - UKSH,Kiel,Germany

(6) Nagoya City University Graduate School of Medical Sciences,Nagoya,Japan

(7) AbbVie Inc.,North Chicago,United States

(8) University of Michigan Health System School of Public Health,Ann Arbor,United States



This item was part of the Randomised controlled trials in IBD II session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019